We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Biomarkers Analyzed for Central Nervous System Lymphoma

By LabMedica International staff writers
Posted on 29 Oct 2019
Print article
Image: A histopathology of primary central nervous system lymphoma showing small purple cells along the blood vessel in the brain (Photo courtesy of Columbia University Medical Center).
Image: A histopathology of primary central nervous system lymphoma showing small purple cells along the blood vessel in the brain (Photo courtesy of Columbia University Medical Center).
Primary central nervous system lymphoma (PCNSL) is a rare type of extranodal non-Hodgkin lymphoma (NHL) accounting for 3% of all newly diagnosed primary intracranial tumors. In patients presenting with focal brain lesions, fast and reliable diagnosis of PCNSL remains a challenge.

A proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) are important factors in the pathophysiology, diagnosis, and prognosis of systemic B cell malignancies. However, their utility as biomarkers for the diagnosis of Central Nervous System Lymphoma (CNSL) and their effects on CNSL cells remain unclear.

Neurologists at the Ludwig Maximilians University (Munich, Germany) and their colleagues analyzed the levels of APRIL and BAFF in the cerebrospinal fluid (CSF) of 116 patients with suspected focal brain lesions, including 53 CNSL patients. Additionally, they serially measured their levels during chemotherapy and relapse. Furthermore, they analyzed the effect of APRIL and BAFF on two B cell lymphoma cell lines using proliferation, viability, and chemotaxis assays.

Enzyme-linked immunosorbent assay (ELISA) kits for APRIL were obtained from BioLegend and ELISA kits for BAFF were obtained from R&D Systems. Other methods used in the study included culturing cell lines, survival assays and chemotaxis assays where migrated cells were counted on a Gallios Flow Cytometer.

The scientists reported that CSF levels of APRIL and BAFF reliably differentiated CNSL from other focal brain lesions (including primary and metastatic brain tumors, autoimmune-inflammatory lesions, and neuroinfectious lesions) with a specificity of 93.7% (APRIL, BAFF) and a sensitivity of 62.3% (APRIL) and 47.1% (BAFF). Serial CSF analysis of CNSL patients during chemotherapy and relapse demonstrates a close correlation of APRIL CSF levels and the course of this disease. In vitro, APRIL and BAFF showed anti-apoptotic effects during methotrexate (MTX) treatment and mediated chemotaxis of malignant B cells.

The authors concluded that CSF levels of APRIL could help establishing the diagnosis of CNSL, especially if stereotactic biopsy is impossible or not conclusive. Moreover, APRIL can serve as a therapeutic marker during therapy and relapse. The study was published on October 15, 2019, in the Journal of Hematology & Oncology.

Related Links:
Ludwig Maximilians University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.